{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408571626
| IUPAC_name = (6''R'',7''R'')-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1''H''-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Latamoxef.svg
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|international|latamoxef}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration = [[Intramuscular injection|Intramuscular]], [[intravenous therapy|intravenous]]
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 35 to 50%
| metabolism = Nil
| elimination_half-life = 2 hours
| excretion = Mostly [[kidney|renal]], unchanged; also biliary
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 64952-97-2
| ATC_prefix = J01
| ATC_suffix = DD06
| PubChem = 47499
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB04570
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 43215
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = VUF6C936Z3
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08109
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 599928
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 74632
<!--Chemical data-->
| C=20 | H=20 | N=6 | O=9 | S=1
| molecular_weight = 520.474 g/mol
| smiles = O=C2N1/C(=C(\CO[C@@H]1[C@]2(OC)NC(=O)C(c3ccc(O)cc3)C(=O)O)CSc4nnnn4C)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JWCSIUVGFCSJCK-CAVRMKNVSA-N
}}
'''Latamoxef''' (or '''moxalactam''') is an [[oxacephem]] [[antibiotic]] usually grouped with the [[cephalosporin]]s. In oxacephems such as latamoxef, the [[sulfur]] atom of the cephalosporin core is replaced with an [[oxygen]] atom.

Latamoxef has been associated with prolonged [[bleeding time]], and several cases of [[coagulopathy]], some fatal, were reported during the 1980s.<ref>{{cite journal |vauthors=Weitekamp MR, Aber RC |title=Prolonged bleeding times and bleeding diathesis associated with moxalactam administration |journal=[[Journal of the American Medical Association|JAMA]] |volume=249 |issue=1 |pages=69–71 |year=1983 |pmid=6217353 |doi=10.1001/jama.249.1.69}}</ref><ref>{{cite journal |vauthors=Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M |title=Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients |journal=Arch Intern Med |volume=146 |issue=11 |pages=2159–64 |year=1986 |pmid=3778044 |doi=10.1001/archinte.146.11.2159}}</ref> Latamoxef is no longer available in the United States. As with other cephalosporins with a methylthiotetrazole side chain, latamoxef causes an [[antabuse]] reaction when mixed with alcohol. Additionally, the methylthiotetrazole side chain inhibits γ-carboxylation of glutamic acid; this can interfere with the actions of vitamin K.

It has been described as a third-generation cephalosporin.<ref name="pmid3296254">{{cite journal |vauthors=Salem RR, McIndoe A, Matkin JA, Lidou AC, Clarke A, Wood CB |title=The hematologic effects of latamoxef sodium when used as a prophylaxis during surgical treatment |journal=Surg Gynecol Obstet |volume=164 |issue=6 |pages=525–9 |date=June 1987 |pmid=3296254 |doi= |url=}}</ref>

== Synthesis ==
Oxa-substituted third generation cephalosporin antibiotic (oxacephalosporin).
[[File:Moxalactam synthesis.svg|thumb|center|700px|Moxalactam synthesis:<ref>M. Narisada, W. Nagata, {{cite patent|DE|2713370}}; eidem, {{US patent|4138486}} (1977, 1979 both to [[Shionogi]]).</ref><ref>{{cite journal|doi=10.1021/jm00193a001|pmid=448673|title=Synthetic studies on β-lactam antibiotics. Part 10. Synthesis of 7β-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7.alpha.-methoxy-3-<nowiki>[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic</nowiki> acid disodium salt (6059-S) and its related 1-oxacephems|journal=Journal of Medicinal Chemistry|volume=22|issue=7|pages=757–9|year=1979|last1=Narisada|first1=Masayuki|last2=Yoshida|first2=Tadashi|last3=Onoue|first3=Hiroshi|last4=Ohtani|first4=Mitsuaki|last5=Okada|first5=Tetsuo|last6=Tsuji|first6=Teruji|last7=Kikkawa|first7=Ikuo|last8=Haga|first8=Nobuhiro|last9=Satoh|first9=Hisashi|last10=Itani|first10=H|last11=Nagata|first11=W|display-authors=9}}</ref><ref>{{cite journal|doi=10.1002/med.2610010302|pmid=6213825|title=Discovery and development of moxalactam (6059-S): The chemistry and biology of 1-oxacephems|journal=Medicinal Research Reviews|volume=1|issue=3|pages=217|year=1981|last1=Otsuka|first1=H.|last2=Nagata|first2=W.|last3=Yoshioka|first3=M.|last4=Narisada|first4=M.|last5=Yoshida|first5=T.|last6=Harada|first6=Y.|last7=Yamada|first7=H.}}</ref><ref>{{cite journal|doi=10.3987/S-1977-02-0839|title=Synthetic Studies on b-Lactam Antibiotics. Part 5. A Synthesis of 7b-Acylamino-3-methyl-1-oxadethia-3-cephem-4-carboxylic Acids|journal=Heterocycles|volume=7|issue=2|pages=839|year=1977|last1=Narisada|first1=Masayuki|last2=Onoue|first2=Hiroshi|last3=Nagata|first3=Wataru}}</ref> (excerpt from Lednicer book 3)]]
The [[benzhydrol]] ester of 6-Aminopenicillanic acid ([[6-APA]]) is S-chlorinated and treated with base whereupon the intermediate [[sulfenyl chloride]] fragments (to '''2'''). Next, displacement with [[propargyl alcohol]] in the presence of [[zinc chloride]] gives predominanntly the stereochemistry represented by diastereoisomer '''3'''. The side chain is protected as the phenylacetylamide; the triple bond is partially reduced with a 5% Pd-CaCO3 ([[Lindlar catalyst]]) and then epoxidized with [[mCPBA]] to give '''4'''. The epoxide is opened at the least hindered end with 1-methyl-1''H''-tetrazole-5-thiol to put in place the future C-3 side chain and give intermediate '''5'''. Jones oxidation followed in turn by ozonolysis (reductive work-up with zinc-AcOH) and reaction with [[SOCl2]] and [[pyridine]] give halide '''6'''. The stage is now wet for intramolecular [[Wittig reaction]]. Displacement with [[PPh3]] and Wittig olefination gives 1-oxacephem '''7'''. Next a sequence is undertaken of side chain exchange and introduction of a 7-methoxyl group analogous to that which is present in [[cephamycins]] and gives them the enhanced [[beta-lactamase]] stability. First '''7''' is converted to the imino chloride with [[PCl5]] and then to the imino methyl ether (with [[methanol]]) and next hydrolyzed to the free amine ('''8'''). Imine formation with 3,5-di-t-butyl-4-hydroxybenzaldehyde is next carried out leading to '''9'''. Oxidation with [[nickel peroxide]] gives iminoquinone methide '''10''', to which methanol is added in a conjugate sense and in the sterechemistry represented by formula '''11'''. The imine is exchanged with [[Girard's reagent T]] to give '''12''', and this is acylated by a suitable protected arylmalonate, as the hemiester hemiacid chloride so as to give 11. Deblocking with [[aluminium chloride]] and anisole gives moxalactam '''14'''.

== References ==
{{Reflist}}

{{CephalosporinAntiBiotics}}

[[Category:Acetaldehyde dehydrogenase inhibitors]]
[[Category:Cephalosporin antibiotics]]
[[Category:Tetrazoles]]
[[Category:Sulfides]]
[[Category:Carboxylic acids]]
[[Category:Lactams]]
[[Category:Ethers]]
[[Category:Propionamides]]
[[Category:Phenols]]
[[Category:Oxygen heterocycles]]


{{antibiotic-stub}}